Conference in May, 2011 in Jurmala arised from the Project European Conference of National Strategies for Chlamydia Trachomatis and Human Papillomavirus-NSCP which has received funding from the European Union, in the framework of the Public Health Programme.
Purpose of the Project is to provide guidance in the European Union about national strategies for Chlamydia trachomatis and human papillomavirus (HPV) early detection and control. It will provide a framework for developing, implementing or improving national strategies to control of Chlamydia trachomatis and HPV. Health policies, like clinical guidelines, should be based on the best available evidence. In this Conference we aimed to facilitate the development of local, evidence-based guidelines within the context of sound national strategies. Such strategies need to take account not only of clinical and epidemiological factors (such as the prevalence in the population) but also of local systems of health care delivery, infrastructure and resourcing.
Target group of the participants included laboratory specialists, clinicians, microbiologists, surveillance experts, public health specialists, healthcare economists, healthcare funders, policy makers.
Objective of the Conference is evaluation and developing of Chlamydia trachomatis and HPV current control programs. Control programs aim to reduce the prevalence diseases, but this is difficult to monitor as it requires periodic population surveys of the population. However, there are many other indicators of the effectiveness which should be built into any program from the outset. At the national level, programs should monitor indicators relating to the policies and guidelines of the program, the implementation and processes, and the outcome of the program. These must be based on the specific objectives appropriate to the level of implementation. If countries move from one level of control to the next, they will need to make decisions based on a rigorous appraisal of the evidence for effectiveness, cost-effectiveness and harms. This will be assisted if countries ensure that all activities are fully evaluated and results shared with others in Europe. This way investments in programs made now will strengthen the evidence base for Chlamydia trachomatis and HPV control and facilitate future decision making and improve population health. At the European level, the objective should be to reduce the proportion of countries reporting no organized activity.